Navigation Links
Shawn P. Cavanagh Appointed Chief Operating Officer of Cambrex
Date:1/7/2011

EAST RUTHERFORD, N.J., Jan. 7, 2011 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM) announced today that, effective January 17, Shawn Cavanagh will join the Company as Executive Vice President and Chief Operating Officer, reporting to Steve Klosk, President and Chief Executive Officer.

Mr. Cavanagh will assume leadership for Cambrex's innovator pharmaceutical contract manufacturing operations, including the related sales, marketing and R&D teams, Cambrex's biocatalysis business and the integration of Cambrex Zenara.  He will directly oversee the Company's new product development programs and partner with our generics leadership team to help grow our generic API business.  Mr. Cavanagh will also play an integral role in strategic planning and M&A activities.

Mr. Cavanagh was most recently at Lonza, where he was the President of Lonza Bioscience, a global business with over $200 million in annual revenues.  Mr. Cavanagh managed Cambrex Bioproducts since 2005, prior to Lonza's purchase of that business from Cambrex in 2007, and held positions of increasing responsibility within that business over nearly 20 years.  He holds a degree in Chemical Engineering, graduating cum laude from the University of New Hampshire.

"We are excited to welcome Shawn back to Cambrex, as he significantly strengthens our leadership team and will allow us to more aggressively execute our plans for growth in existing and developing markets.  A key focus will be to accelerate our new product development activities, with a particular emphasis on utilizing our chemistry, biocatalysis and formulation technology platforms. Shawn has a strong track record in leading complex global businesses and delivering growth, having led our Bioproducts business during a period when it was introducing several new products each year and growing at double digit rates," said Steve Klosk, President and CEO.

About Cambrex

Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products.  For more information, please visit www.cambrex.com.


'/>"/>
SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Netsmart Technologies Software Supports Shawnee Mental Health Center Integrated Mental Health and Primary Care Initiative
2. Former Miss USA Shawnae Jebbia Shines with Siemens Pure
3. Foundation Radiology Group Adds Shawn Kramer, Director of Client Services
4. Christopher Codeanne Appointed Chief Financial Officer of Premier Research Group
5. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
6. Dr. Ludo Reynders Appointed Chief Executive Officer of Premier Research Group
7. OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
8. Mark S. Rangell Appointed Chief Operating Officer for Sandata Technologies, LLC
9. Robert F. Walters Appointed Chairman of the Board of Directors of ORBIS International
10. Caraco Pharmaceutical Laboratories, Ltd. Announces G.P. Singh Sachdeva Is Appointed as Chief Operating Officer
11. Helix Bioscience Appointed DNA Drug Sensitivity Testing Distributor for Genelex Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 27, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES CORP. ("Invictus ... Invictus MD is pleased to announce it has received ... on the TSX Venture Exchange.  Receiving ... year of significant achievements for Invictus-MD. Some of which ... at AB Laboratories Inc. ("AB Labs"), a Licensed Producer ...
(Date:3/27/2017)... YORK , March 27, 2017 ... colors as the NASDAQ Composite closed the trading session ... lower; and the S&P 500 was down 0.08%. US ... nine sectors finishing the day in green. Pre-market today, ... Wright Medical Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: ...
(Date:3/27/2017)... YORK , March 27, 2017 /PRNewswire/ ... technology platform for value-based precision medicine, today ... collaboration with Novartis Pharmaceuticals Corporation to help ... cancer patients. As part of ... previous announced collaboration entered into January 2016, ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... New patients who ... replace their missing teeth can now have them placed by Dr. Manju Kejriwal, with ... i-CAT® Cone Beam technology to increase the accuracy of each dental implant placement. The ...
(Date:3/27/2017)... ... 27, 2017 , ... This is the second major release ... in 2014. It is the culmination of collaborative efforts by members of the ... Organizational Member Zato Health co-funded the ONC certification and provided key technical support ...
(Date:3/27/2017)... , ... March 27, 2017 , ... Buzzies parent company, ... 10 for Rent the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her ... April 8. , Project Entrepreneur’s second annual venture competition ignites bold ideas by ...
(Date:3/27/2017)... ... 2017 , ... The Case Management Society of America (CMSA) will install six ... CMSA’s membership has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve ... VA Advisory position has also been added to the BOD, per an appointment made ...
(Date:3/27/2017)... Orion, Michigan (PRWEB) , ... March 27, 2017 ... ... results. The comprehensive weight management program at Women’s Excellence will help patients ... initial evaluation and physical exam. The specialists at Women's Excellence will measure ...
Breaking Medicine News(10 mins):